Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118147 | 0.93 | ADORA1 (0.57) | ADORA1ADORA2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL10118213 | 0.91 | ADORA1 (0.53) | ADORA1ADORA2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL10118228 | 0.89 | ADORA2A (0.46) | ADORA1ADORA2A | |
| Hydrochloric Acid SCHEMBL414208 | 0.88 | ADORA1 (0.62) | ADORA1ADORA2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL10118239 | 0.88 | ADORA2A (0.46) | ADORA1ADORA2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL10118271 | 0.83 | ADORA1 (0.45) | ADORA1ADORA2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL414200 | 0.81 | ADORA1 (0.73) | ADORA1ADORA2ACACNA2D1CACNA1BCACNB1 | |
| Hydrochloric Acid SCHEMBL414128 | 0.81 | ADORA1 (0.72) | ADORA1ADORA2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL10118230 | 0.81 | ADORA1 (0.42) | ADORA1ADORA2A | |
| SCHEMBL10118205 | 0.80 | ADORA1 (0.50) | ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885CACNA2D1 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.